Amneal Pharmaceuticals

Amneal Pharmaceuticals is an American pharmaceutical company that develops, manufactures and markets generic medicines and a growing portfolio of specialty and branded products. It was founded in 2002 by brothers Chirag Patel and Chintu Patel, who built the business from a small generics operation into one of the larger US-based generics manufacturers. The company is headquartered in Bridgewater, New Jersey, and its shares trade on the New York Stock Exchange under the ticker AMRX. Amneal's core business is complex and conventional generic pharmaceuticals — tablets, capsules, oral solids, injectables and other dosage forms — sold largely in the United States, where it is among the significant domestic generics suppliers. Alongside generics, the company has expanded into specialty areas such as central nervous system treatments, Parkinson's disease therapies and other branded or value-added products, and it also produces active pharmaceutical ingredients and operates manufacturing capacity that supports both its own portfolio and contract work. Over its history Amneal has grown through a combination of organic expansion and acquisitions, broadening its manufacturing footprint and product pipeline. Its positioning rests on affordable, high-quality medicines, vertical integration in development and manufacturing, and a diversified product mix spanning generics, specialty brands and pharmaceutical ingredients. The company serves pharmacies, wholesalers, hospitals and patients, and presents itself as a partner for accessible healthcare. As a public company, Amneal reports to investors and is subject to US regulatory oversight, including FDA requirements for its manufacturing facilities and product approvals. Its brand identity is tied to reliable supply of generic medicines and to a strategy of moving up the value chain into more complex and specialty products.

Amneal Pharmaceuticals was founded in 2002 by brothers Chirag Patel and Chintu Patel, who started the company as a generics venture and grew it into a vertically integrated pharmaceutical manufacturer. From its New Jersey base, the company built out development and manufacturing capabilities for oral solid dosage forms and other generic products, positioning itself as a domestic US supplier in a market long dominated by larger international players. Through the 2000s and 2010s Amneal expanded its product portfolio and manufacturing footprint, adding capacity and moving into more complex generic formulations. A significant turning point came in 2018, when Amneal combined with Impax Laboratories, creating a larger combined generics and specialty business that broadened its product range and specialty presence. The combined company continued to operate as Amneal Pharmaceuticals and remained listed on the New York Stock Exchange. In the years that followed, Amneal focused on strengthening its generics pipeline, investing in complex products and injectables, and building a specialty portfolio that includes treatments in areas such as central nervous system and Parkinson's disease. The company also emphasized its role as a US-based manufacturer of essential medicines, a positioning that gained prominence amid broader concerns about pharmaceutical supply-chain resilience. Amneal has continued to pursue acquisitions and partnerships to add products and capabilities, while managing the regulatory requirements that govern pharmaceutical manufacturing. Its history reflects the trajectory of a founder-led generics business that scaled into a diversified public pharmaceutical company serving the US and international markets.

• 2018

  Amneal combines with Impax Laboratories, expanding its generics and specialty portfolio.

• 2002

  Amneal Pharmaceuticals founded by Chirag Patel and Chintu Patel.

A US-based generics and specialty pharmaceutical company focused on affordable, high-quality medicines and vertically integrated development and manufacturing.

• Generic oral solid dosage medicines

• Complex generic pharmaceuticals

• Injectable products

• Active pharmaceutical ingredients

• CNS and Parkinson's specialty products

• 2019

  Amneal recalls ranitidine products over potential NDMA impurity

  Amneal Pharmaceuticals issued a voluntary consumer-level recall of specified ranitidine tablets and syrup because they could contain NDMA amounts above levels established by the FDA. The article reports no confirmed adverse events directly related to the recall.

  Source

Read more

• 2026.08.10

  Reported2026.08.17

  Amneal Pharmaceuticals completes acquisition of Kashiv BioSciences[3]Amneal Pharmaceuticals完成对Kashiv BioSciences的收购mondaq.com

  Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences for up to $1.1 billion, creating a fully integrated global biosimilars platform. Terms included $375 million in cash, $375 million in equity at closing, and up to $350 million in additional milestone and contingent payments.

• 2020.04.08

  Reported2020.04.08

  Amneal announces increased hydroxychloroquine production[4]Amneal宣布扩大羟氯喹产量businesstoday.in

  Amneal Pharmaceuticals announced that it was ramping up hydroxychloroquine sulphate production at several manufacturing sites and expected to produce approximately 20 million tablets by mid-April.

• Unconfirmed

  Reported2019.11.26

  Amneal recalls ranitidine products over potential NDMA impurity[2]Amneal recalls ranitidine products over potential NDMA impuritypharmacytimes.com

  Amneal Pharmaceuticals issued a voluntary consumer-level recall of specified ranitidine tablets and syrup because they could contain NDMA amounts above levels established by the FDA. The article reports no confirmed adverse events directly related to the recall.

Read more

1. 1Amneal Pharmaceuticals official websiteamneal.com
2. 2Amneal recalls ranitidine products over potential NDMA impuritypharmacytimes.com
3. 3Amneal Pharmaceuticals完成对Kashiv BioSciences的收购mondaq.com
4. 4Amneal宣布扩大羟氯喹产量businesstoday.in
5. 5COVID-19: Indian American’s US pharma firm donates 3.4 million Hydroxychloroquine Sulphate tabletsoneindia.com
6. 6Hydroxychloroquine Export to US: Indian American's US pharma firm donates 3.4 million hydroxychloroquine tablets | International Business News - Times of Indiatimesofindia.indiatimes.com